1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

ViiV Two-Drug HIV Pill Juluca Close To Europe Okay

 
• By Kevin Grogan

The likely EMA approval of Juluca challenges the traditional HIV treatment paradigm of a three-drug regimen, with the single tablet, two-drug regimen offering the same efficacy as well as reduced toxicity and greater convenience.

Scales
Two beats three? ViiV's Juluca is a single-pill, two-drug regimen • Source: Shutterstock

ViiV Healthcare is a step closer to getting approval for the first single-pill, two-drug HIV regimen on this side of the Atlantic after the European Medicines Agency's scientific committee granted a positive opinion to Juluca (dolutegravir/rilpivirine).

 The Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Juluca, which combines ViiV's integrase inhibitor Tivicay (dolutegravir) with Johnson & Johnson's non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed on a stable antiretroviral regimen for at least six months

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.